Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 564–565 (2005)Cite this article

boxed-textPaoluzi OA et al. (2005) Comparison of two different daily dosages (2.4 vs 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 21: 1111–1119

Encouraging adherence to treatment for ulcerative colitis matters more than the dose of oral mesalazine to maintain remission: topical therapy should be added for patients who relapse on oral therapy alone

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sutherland L et al. (2002) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 4: CD000544

    Google Scholar 

  2. Bebb JR and Scott BB (2004) Systematic review: how effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 20: 143–149

    Article  CAS  Google Scholar 

  3. Hanauer SB et al. (2005) Efficacy and safety of mesalazine 4.8 g/day (800 mg tablet) compared with 2.4 g/day (400 mg tablet) in treating moderately active ulcerative colitis: ASCEND II study [abstract]. Gut 53 (Suppl 2): A3

    Google Scholar 

  4. Travis SPL et al. (1994) The optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 35: 1282–1286

    Article  CAS  Google Scholar 

  5. Frieri G et al. (2005) Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 37: 92–96

    Article  CAS  Google Scholar 

  6. Kane S et al. (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114: 39–43

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Katy Cherry, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Consultant Gastroenterologist and Clinical Director of the Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK

    Simon Travis

Authors
  1. Simon Travis
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author is in receipt of unrestricted educational grants, or consultancy fees or lecturing fees from Celltech, Ferring Pharmaceuticals, Proctor and Gamble, and Shire Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Travis, S. What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?. Nat Rev Gastroenterol Hepatol 2, 564–565 (2005). https://doi.org/10.1038/ncpgasthep0336

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0336

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing